Boehringer Ingelheim steps up investment in R&D

Boehringer Ingelheim, the German pharma giant whose North American headquarters are in Ridgefield, reports that despite the pandemic, it maintained momentum in 2020.

The company stepped up its investments in R&D by 7% from 2019, to $4.2 billion – the highest annual investment in R&D in its 136-year history.